I am a
Home I AM A Search Login

Papers of the Week

2020 Sep-Oct

Clin Exp Rheumatol



Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.


Strand V, van der Heijde D, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song Y-W, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R
Clin Exp Rheumatol. 2020 Sep-Oct; 38(5):848-857.
PMID: 31858963.


Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we present data from the completed Phase 3 randomised controlled trial (RCT) ORAL Scan (NCT00847613), which evaluated the impact of tofacitinib on patient-reported outcomes (PROs) through 24 months in patients with active RA and inadequate responses to methotrexate (MTX-IR).